An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages 1274-1281

  Viscoli, C ^a   Herbrecht, R ^b   Akan, H ^c   Baila, L ^d   Sonet, A ^e   Gallamini, A ^f   Giagounidis, A ^g   Marchetti, O ^h   Martino, R ⁱ   Meert, L ^d   Paesmans, M ^j   Ameye, L ^j   Shivaprakash, M ^k   Ullmann, A J ^l   Maertens, J ^m  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c ANKARA UNIVERSITY   (Turkey)

^d EORTC DATA CENTER   (Belgium)

^e UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^f S CROCE E CARLE HOSPITAL   (Italy)

^g ST JOHANNES HOSPITAL   (Germany)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ University Hospital   (Spain)

^j JULES BORDET INSTITUTE   (Belgium)

^k MERCK RESEARCH LABORATORIES   (United States)

^l JOHANNES GUTENBERG UNIVERSITY   (Germany)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Acute leukaemia; Echinocandins; Fungal infections

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; ITRACONAZOLE; POTASSIUM; VORICONAZOLE; ECHINOCANDIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNGUS CULTURE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BLOOD DISEASE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ECHINOCANDINS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76249115229     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp355     Document Type: Article

References (16)

1. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with haematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
2. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after haematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centres. Clin Infect Dis 2006; 42: 955-63.
3. Upton A, Kirby DA, Carpenter P et al. Invasive aspergillosis following haematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
4. Lin S, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
5. Ribaud P, Chastang C, Latge JP et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-30.
6. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
7. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-70.
8. Ascioglu S, Rex JH, de Pau B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
9. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
10. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
11. Cornely O, Maertens J, Bresnkik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
12. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
13. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
14. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
15. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
16. Segal B, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674 83.